Several clinical studies [38, 39] have demonstrated that the tyrosine kinase receptor inhibitor Nintedanib is a secure and proficient treatment for IPF patients by diminishing the FVC decline rate. This evidence concerns the gene NTRK1 and idiopathic pulmonary fibrosis.